RecruitingOvarian CancerEpithelial Ovarian CancerSerous Ovarian Tumor
A Study of Isoquercetin in People With Ovarian Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Sponsor: Memorial Sloan Kettering Cancer Center
You may qualify if…
- ✓ Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings.
- ✓ Minimum age 18 years
- ✓ Life expectancy of greater than 6 months.
- ✓ ECOG performance status \<2
- ✓ Participants must have preserved organ and marrow function as defined below:
- ✓ Platelet count \> 50,000/mcL
- ✓ Prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 x institutional upper limit of normal (ULN)
- ✓ Total bilirubin \< 3 x ULN without liver metastases and \<5 x ULN in presence of liver metastases.
You may not qualify if…
- ✕ Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation)
- ✕ Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer)
- ✕ History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months
- ✕ Familial bleeding diathesis
- ✕ Known diagnosis of disseminated intravascular coagulation (DIC)
- ✕ Currently receiving anticoagulant therapy
- ✕ Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen \> 800 mg daily or equivalent)
- ✕ Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Where it's recruiting
Massachusetts
Boston
New Jersey
Basking Ridge · Middletown · Montvale
New York
Commack · Harrison · New York · Rockville Centre
Source: ClinicalTrials.gov · NCT07303894 · last updated 2026-04-16